Immatics IMTX Stock
Immatics Price Chart
Immatics IMTX Financial and Trading Overview
| Immatics stock price | 9.91 USD |
| Previous Close | 9.78 USD |
| Open | 9.95 USD |
| Bid | 7.15 USD x 200 |
| Ask | 12.54 USD x 200 |
| Day's Range | 9.7 - 10.13 USD |
| 52 Week Range | 5.05 - 12.41 USD |
| Volume | 457.04K USD |
| Avg. Volume | 466.06K USD |
| Market Cap | 1.34B USD |
| Beta (5Y Monthly) | 1.303 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.96 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.78 USD |
IMTX Valuation Measures
| Enterprise Value | 898.17M USD |
| Trailing P/E | N/A |
| Forward P/E | -5.1639743 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 35.83933 |
| Price/Book (mrq) | 2.556476 |
| Enterprise Value/Revenue | 24.082 |
| Enterprise Value/EBITDA | -4.404 |
Trading Information
Immatics Stock Price History
| Beta (5Y Monthly) | 1.303 |
| 52-Week Change | 80.44% |
| S&P500 52-Week Change | 24.48% |
| 52 Week High | 12.41 USD |
| 52 Week Low | 5.05 USD |
| 50-Day Moving Average | 10.71 USD |
| 200-Day Moving Average | 9.8 USD |
IMTX Share Statistics
| Avg. Volume (3 month) | 466.06K USD |
| Avg. Daily Volume (10-Days) | 414.26K USD |
| Shares Outstanding | 136.67M |
| Float | 69.59M |
| Short Ratio | 8.78 |
| % Held by Insiders | 17.58% |
| % Held by Institutions | 79.85% |
| Shares Short | 4.8M |
| Short % of Float | 5.08% |
| Short % of Shares Outstanding | 3.50% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -867.89% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -22.43% |
| Return on Equity (ttm) | -43.20% |
Income Statement
| Revenue (ttm) | 37.3M USD |
| Revenue Per Share (ttm) | 0.3 USD |
| Quarterly Revenue Growth (yoy) | -59.00000000000000000000000000000000% |
| Gross Profit (ttm) | -163814000 USD |
| EBITDA | -203930000 USD |
| Net Income Avi to Common (ttm) | -214406000 USD |
| Diluted EPS (ttm) | -1.99 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 453.57M USD |
| Total Cash Per Share (mrq) | 3.32 USD |
| Total Debt (mrq) | 15.08M USD |
| Total Debt/Equity (mrq) | 3.31 USD |
| Current Ratio (mrq) | 8.775 |
| Book Value Per Share (mrq) | 3.8255785 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -184463008 USD |
| Levered Free Cash Flow (ttm) | -110854376 USD |
Profile of Immatics
| Country | United States |
| State | N/A |
| City | Tübingen |
| Address | Paul-Ehrlich-Strasse 15-19 |
| ZIP | 72076 |
| Phone | 49 7071 5397 0 |
| Website | https://www.immatics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 678 |
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Q&A For Immatics Stock
What is a current IMTX stock price?
Immatics IMTX stock price today per share is 9.91 USD.
How to purchase Immatics stock?
You can buy IMTX shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Immatics?
The stock symbol or ticker of Immatics is IMTX.
Which industry does the Immatics company belong to?
The Immatics industry is Biotechnology.
How many shares does Immatics have in circulation?
The max supply of Immatics shares is 136.67M.
What is Immatics Price to Earnings Ratio (PE Ratio)?
Immatics PE Ratio is now.
What was Immatics earnings per share over the trailing 12 months (TTM)?
Immatics EPS is -1.96 USD over the trailing 12 months.
Which sector does the Immatics company belong to?
The Immatics sector is Healthcare.
Immatics IMTX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25587.04 USD — |
-2.21
|
13.85B USD — | 25513.26 USD — | 25882.57 USD — | — - | 13.85B USD — |
|
US Tech Health Care
IXHC
US
|
1184.66 USD — |
+0.75
|
— — | 1174.72 USD — | 1192.68 USD — | — - | — — |
- {{ link.label }} {{link}}